Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8028137 | 0.89 | CNR2 (0.48) | NPC1GAARAB9ASMN1; SMN2PPARG | |
| SCHEMBL6159720 | 0.83 | ITK (0.46) | NPC1GAARAB9ASMN1; SMN2BRD4 | |
| SCHEMBL6486632 | 0.81 | F2 (0.50) | NPC1GAARAB9ASMN1; SMN2BRD4 | |
| SCHEMBL6638588 | 0.81 | GAA (0.44) | NPC1GAARAB9ASMN1; SMN2BRD4 | |
| Hydrochloric Acid SCHEMBL7244675 | 0.80 | F2 (0.49) | NPC1GAARAB9ASMN1; SMN2BRD4 | |
| SCHEMBL7244672 | 0.80 | F2 (0.47) | NPC1GAARAB9ASMN1; SMN2BRD4 | |
| SCHEMBL6159759 | 0.80 | KMT2A (0.58) | NPC1RAB9ASMN1; SMN2CNR2KCNJ1 | |
| SCHEMBL7509579 | 0.80 | NPC1 (0.48) | NPC1GAARAB9ASMN1; SMN2BRD4 | |
| SCHEMBL6475543 | 0.78 | KDM4E (0.48) | NPC1RAB9ASMN1; SMN2NTRK1NTRK2 | |
| SCHEMBL6159112 | 0.78 | NPC1 (0.41) | NPC1GAARAB9ASMN1; SMN2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237877-B1 | CARBOXAMIDE-SUBSTITUTED BENZIMIDAZOL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-07-27 | — | — | EP | disclosed |
| EP-1504041-A1 | PROCESS FOR REDUCING RESIDUAL FREE RADICAL POLYMERIZABLE MONOMER CONTENT OF POLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2005-02-09 | — | — | EP | disclosed |
| EP-1100795-B1 | DISUBSTITUTED BICYCLIC HETEROCYCLES HAVING, IN PARTICULAR, A THROMBIN INHIBITIVE EFFECT | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-06-09 | — | — | EP | disclosed |
| US-6656956-B2 | Tryptase inhibitor; antiinflamamtory agents, antiallergens | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
| WO-2003093328-A1 | PROCESS FOR REDUCING RESIDUAL FREE RADICAL POLYMERIZABLE MONOMER CONTENT OF POLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-1220845-B1 | ARYL-SULFONAMIDE SUBSTITUTED BENZIMIDAZOL DERIVATIVES AND USE OF SAID AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-08-13 | — | — | EP | disclosed |
| US-20030105137-A1 | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1220844-B1 | ARYL SULFONAMIDE-SUBSTITUTED BENZIMIDAZOL DERIVATIVES THEREOF AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-04-09 | — | — | EP | disclosed |
| EP-1237877-A2 | CARBOXAMIDE-SUBSTITUTED BENZIMIDAZOL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM KG (DE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002062785-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE THEREOF AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
| EP-1220845-A1 | ARYL-SULFONAMIDE SUBSTITUTED BENZIMIDAZOL DERIVATIVES AND USE OF SAID AS TRYPTASE INHIBITORS | Boehringer Ingelheim Pharma KG (DE) | 2002-07-10 | — | — | EP | disclosed |
| EP-1220844-A1 | ARYL SULFONAMIDE-SUBSTITUTED BENZIMIDAZOL DERIVATIVES THEREOF AS TRYPTASE INHIBITORS | Boehringer Ingelheim Pharma KG (DE) | 2002-07-10 | — | — | EP | disclosed |
| US-6413990-B1 | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-07-02 | — | — | US | disclosed |
| US-6407130-B1 | ANTIALLERGENS, ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM, GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-18 | — | — | US | disclosed |
| US-6365584-B1 | FOR PROPHYLAXIS AND THERAPY OF INFLAMMATORY AND/OR ALLERGIC DISEASES, LUNG FIBROSIS, FIBROSING ALVEOLITIS AND SCARRING, COLLAGENOSES SUCH AS LUPUS ERYTHEMATODES AND SCLERODERMIA AS WELL AS ARTERIOSCLEROSIS, PSORIASIS AND NEOPLASM | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-04-02 | — | — | US | disclosed |
| WO-2001034572-A2 | CARBOXAMIDE-SUBSTITUTED BENZIMIDAZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001023360-A1 | ARYL SULFONAMIDE-SUBSTITUTED BENZIMIDAZOL DERIVATIVES THEREOF AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001023359-A1 | ARYL-SULFONAMIDE SUBSTITUTED BENZIMIDAZOL DERIVATIVES AND USE OF SAID AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-05 | — | — | WO | disclosed |
| US-6121308-A | INDOLE AND BENZIMIDAZOLE ANTITHROMBOTIC COMPOUNDS, SUCH AS 1-METHYL-2-(N-(4-AMIDINOPHENYL)-AMINOMETHYL)-5-(N-(HYDROXYCARBONYLMETHYL) -QUINOLINE-8-SULPHONYLAMINO)-INDOLE | BOEHRINGER INGELHEIM KG (DE) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105137-A1 | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions | CMA1, TPSD1, TPSAB1 | NPC1 3133/4885GAA 25/4885RAB9A 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.